Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
CK-101 is a novel, potent, small molecule tyrosine kinase inhibitor (TKI) that selectively
targets mutant forms of the epidermal growth factor receptor (EGFR) while sparing wild-type
(WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK) and safety
profile of oral CK-101; to determine the maximum tolerated dose (MTD) and/or recommended
Phase 2 dose (RP2D) of oral CK-101; to assess the safety and efficacy of CK-101 in
treatment-naive NSCLC patients known to have activating EGFR mutations and previously treated
NSCLC patients known to have the T790M EGFR mutation.